Healios KK

Healios K.K. and its subsidiaries research, develop, manufacture, and sell cell therapy and regenerative medicine products in Japan, Europe, and the United States. Its pipeline includes HLCM051, which is preparing for approval for acute respiratory distress syndrome, preparing for a phase 3 trial for ischemic stroke, and in a phase 2 trial for trauma. It also has HLCR011 in a phase 1/2 trial for retinal pigment epithelium and age-related macular degeneration, and AKT-01/HLCN061 in pre-clinical trials for mesothelioma, lung cancer, hepatocellular carcinoma, and gastric cancer (solid tumors). The company also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. Formerly Retina Institute Japan, K.K., it changed its name to Healios K.K. in September 2013, was incorporated in 2011, and is headquartered in Chiyoda, Japan.

Biotech & Genomic Medicine▲

Healios announces Chinese patent grant for next-generation iPS cell UDC

Healios announced on the 19th that a patent has been registered in China for its next-generation iPS cell, the Universal Donor Cell, or UDC, created using gene-editing technology. The UDC is a low-immunogenic iPS cell made by removing polymorphic HLA through gene editing and introducing HLA-G, PD-L1, and PD-L2, giving it resistance to both adaptive and innate immunity. A suicide gene has also been introduced as a safety switch, and the company says the UDC is expected to serve as a next-generation technology platform for creating regenerative medicine products as a raw material for transplanted cells.

4593.JP ▲

Biotech & Genomic Medicine ▲

トレーダーズ・ウェブ·30dRead more →